Efficacy and safety of dinaciclib versus ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia

To the editor: Novel approaches targeting molecules involved in intracellular pathways that are crucial for the survival and proliferation of the leukemic clone have been recently approved for the treatment of chronic lymphocytic leukemia (CLL) patients. Nevertheless, CLL remains incurable outside